Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCSZ11 Monotherapy and Combinations in Advanced Solid Tumors
NCT05785754Phase 1Recruiting
- Sponsor
- DynamiCure Biotech
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of DCSZ11 in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 2 more (4 arms), sponsored by DynamiCure Biotech. Primary endpoints: Incidence of Dose Limiting Toxicities at 21 days, Treatment Emergent Adverse Events at 3 years and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
DCSZ11
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)soft tissue sarcoma (STS)Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05785754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785754.